Belapectin

Belapectin
Clinical data
Other names	GR-MD-02; Galactoarabino-rhamnogalacturonate;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name α-D-Galacturono-α-D-galacto-β-D-galacto-6-deoxy-α-L- manno-α-L-arabinan, (1→2),(1→3),(1→4)-, methyl ester;
CAS Number	1980787-47-0; 1604015-18-0;
DrugBank	DB15125;
UNII	K7ODU55HT6;

Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics for the treatment of non-alcoholic steatohepatitis.^[1]^[2]^[3]^[4] In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension.^[5]

Other names

GR-MD-02
Galactoarabino-rhamnogalacturonate

Legal status

Investigational

CAS Number

DrugBank

DB15125

Quick facts Clinical data, Other names ...

Close

[1]

[2]

[3]

[4]

[5]

Belapectin

References

Related Articles

Clinical data
Other names	GR-MD-02 Galactoarabino-rhamnogalacturonate
Legal status
Legal status	Investigational
Identifiers
IUPAC name α-D-Galacturono-α-D-galacto-β-D-galacto-6-deoxy-α-L- manno-α-L-arabinan, (1→2),(1→3),(1→4)-, methyl ester
CAS Number	1980787-47-0 1604015-18-0
DrugBank	DB15125
UNII	K7ODU55HT6